Valrubicin

FDA Approved: * April 19, 2019
Pharm Company: * CUSTOPHARM INC
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Valrubicin Overview

Valrubicin (N-trifluoroacetyladriamycin-14-valerate, trade name Valstar) is a chemotherapy drug used to treat bladder cancer. Valrubicin is a semisynthetic analog of the anthracycline doxorubicin, and is administered by infusion directly into the bladder. It was originally launched as Valstar in the U.S. in 1999 for intravesical therapy of Bacille Calmette-Guérin (BCG)-refractory carcinoma in situ of the urinary bladder in patients in whom cystectomy would be associated with unacceptable...

Read more Valrubicin Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Valrubicin

Recent Valrubicin Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

NDC Database Records for Valrubicin: (1 result)

Sorted by National Drug Code

• 24201-101 Valrubicin Intravesical Solution Intravesical Solution 40 mg/ml Intravesical Solution, Concentrate by Leucadia Pharmaceuticals

Other drugs which contain Valrubicin or a similar ingredient: (1 result)

• VALSTAR Valrubicin